Profile: Vical Inc (VICL.O)
23 Jun 2017
Vical Incorporated, incorporated on April 30, 1987, researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including a Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, including invasive Aspergillus, which are causes of morbidity and mortality in immunocompromised patients, including transplant recipients, and a completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant to prevent CMV infection before and during pregnancy.
HSV-2 is a member of the herpes virus family and is the cause of recurrent genital herpes worldwide. The Company has initiated a Phase I/II trial of its Vaxfectin formulated therapeutic vaccine for HSV-2. The Company is developing its CMV vaccines, including ASP0113 (TransVax) and CyMVectin. ASP0113 is designed to serve the patient population by preventing CMV reactivation or infection in transplant recipients. CyMVectin is designed to serve the patient population by preventing primary CMV infection during pregnancy and thereby precluding maternal-fetal CMV transmission, congenital CMV infection and related birth defects. ASP0113 is a plasmid DNA vaccine that induces both T-cell and antibody responses by expressing the phosphoprotein (pp65) and Glycoprotein B (gB) antigens. The tegument protein, pp65, is an antigen recognized by T cells in CMV-infected individuals. The gB protein is a surface antigen of CMV and a primary target of neutralizing antibodies. The vaccine is also formulated with poloxamer CRL1005. CyMVectin consists of plasmid DNA (pDNA) that encodes the human CMV gB antigen with pDNA that encodes the human CMV phosphoprotein 65 antigen. The product is formulated with its lipid-based adjuvant Vaxfectin. CyMVectin was designed to prevent CMV infection prior to pregnancy. It has initiated a Phase I clinical trial of its antifungal candidate, VL-2397. The Company had developed several vaccines targeted at diseases, including malaria, anthrax, severe acute respiratory syndrome (SARS), West Nile Virus (WNV) and Ebola.
The Company competes with Sanofi, Novartis, GlaxoSmithKline plc, AstraZeneca, Merck, Pfizer Inc., Roche, AiCuris GmbH & Co. KG and Chimerix, Inc.
10390 Pacific Center Ct
SAN DIEGO CA 92121-4340
Company Web Links
- BRIEF-Vical presents phase 1 VL-2397 data at June ASM microbe 2017 meeting supporting advancement to phase 2
- BRIEF-Vical Q1 loss per share $0.25
- BRIEF-Vical reports outcome of Phase 1 trial of VL-2397
- BRIEF-AnGes MG plans cooperation with Vical Inc on development of genetic medication for Chronic Hepatitis B
- BRIEF-Vical reports Q4 revenue of $3.2 million